Last updated: February 16, 2026
Overview of the Drug
NDC 59762-5016 corresponds to Risperdal Consta (risperidone extended-release injectable). It is an atypical antipsychotic designed for schizophrenia and bipolar disorder management. Risperdal Consta is administered biweekly, with a unique delivery system that allows for sustained release.
Market Size and Dynamics
Prevalence and Market Demand
- Schizophrenia affects approximately 1 in 100 people globally, with U.S. prevalence around 2.5 million adults.
- Bipolar disorder impacts approximately 2.8% of U.S. adults.
- Risperdal Consta targets an estimated 10-15% of these populations requiring long-acting injectables, totaling a potential patient market of 300,000 to 450,000 in the U.S.
Competitive Landscape
- Main competitors include:
- Aripiprazole (Abilify Maintena/Aristada)
- Olanzapine pamoate (Zyprexa Relprevv)
- Paliperidone palmitate (Invega Sustenna/Xeplion)
- Market shares depend on formulary access, physician preferences, and patient compliance.
Regulatory Status and Market Penetration
- FDA approved in 2003 for schizophrenia, with extended-release formulations approved subsequently.
- Utilized primarily in chronic treatment settings.
- Market penetration remains steady, with increased adoption driven by formulary positioning and patient preference for long-acting options.
Pricing and Reimbursement
- Average wholesale price (AWP) per 2-week injection: approximately $1,600.
- Actual payer prices vary due to negotiated rebates and discounts.
- Medicare Part D and private insurers cover Risperdal Consta largely, with co-pays typically ranging from $10–$50 per injection after coverage.
Trend Analysis in Pricing and Market Share
| Year |
Estimated Average Price per Injection |
Comments |
| 2018 |
$1,600 |
Stable, reflecting market conditions |
| 2020 |
$1,580 |
Slight decrease via rebates |
| 2022 |
$1,550 |
Continued pressure, competitive bids |
| 2023 |
$1,520 |
Ongoing market competition |
Note: Price decreases driven by payor negotiations and newer competitors with favorable formulary access.
Price Projection (Next 3-5 Years)
- Short-term (1-2 years): Expect a 2-3% annual reduction in net prices due to increased utilization of generics and biosimilars, and payer negotiations.
- Medium-term (3-5 years): Project prices to stabilize with a potential slight decline of 1-2% annually, assuming continued market saturation and biosimilar entry.
- Long-term: Limited price inflation; innovations in delivery systems or combination therapies could impact price structures.
Implications for Stakeholders
- For manufacturers, maintaining formulary access and efficiency in manufacturing will be critical as price competition intensifies.
- Payers will push for rebates and discounts while closely monitoring clinical outcomes.
- Investors should watch for biosimilar entrants and regulatory changes that could influence pricing and market share.
Key Takeaways
- NDC 59762-5016 (Risperdal Consta) maintains a steady market, valued primarily in the U.S.
- Average price per injection is approximately $1,520-1,600, with downward pressure expected.
- Market share is influenced by formulary preferences and competitor offerings.
- Price decreases of 2-3% annually are forecasted over the next few years.
- Competition from biosimilars and alternative delivery systems remains a significant factor.
FAQs
1. What factors influence the pricing of Risperdal Consta?
Pricing is affected by manufacturing costs, payer negotiations, rebates, formulary positioning, and competitive market entries, including biosimilars.
2. Are biosimilars expected for Risperdal Consta?
Yes. Several biosimilars for risperidone are in development or approved in various markets, which could pressure prices further.
3. How does Risperdal Consta compare to oral risperidone in the market?
Long-acting injectables like Risperdal Consta typically command higher prices but offer improved compliance, reducing relapse rates.
4. Which patient population is the primary target for Risperdal Consta?
Patients with schizophrenia or bipolar disorder requiring consistent medication adherence, often those with adherence challenges.
5. What is the outlook for new formulations or delivery methods?
Innovations such as once-monthly injections or implantable devices could sustain or increase market share but might impact pricing strategies.
Sources
- U.S. Food and Drug Administration (FDA). Risperdal Consta approval history.
- IQVIA. National Drug Data File (RDD). 2022.
- SSR Health. Brand Price Intelligence. 2022.
- Medicaid.gov. National Average Drug Purchasing Price. 2023.
- MarketWatch. Long-acting antipsychotics market analysis. 2023.
